Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Related Content

Brief Version
Full Version

Non-Nucleoside Reverse Transcriptase Inhibitors

Etravirine (Intelence, ETR)

Last Updated: December 7, 2018; Last Reviewed: December 7, 2018

Excerpt from Table 10a
Generic Name
(Abbreviation)
Trade Name		 Formulation Dosing Recommendations Use in Pregnancy
Etravirine
(ETR)
Intelence 		Tablets:
  • 25 mg
  • 100 mg
  • 200 mg
For patients unable to swallow tablets whole, the tablets may be dispersed in a glass of water. 		Standard Adult Dose:
  • 200 mg twice daily with food

PK in Pregnancy:
  • PK data in pregnancy (n = 26) suggest that etravirine exposure during pregnancy increases 1.2-fold to 1.6-fold.

Dosing in Pregnancy:
  • No change in dose indicated.
 Variable placental transfer, usually in the moderate to high categories, ranging from 0.19–4.25 (data from 19 mother-infant pairs).b

Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:
          High: >0.6
          Moderate: 0.3–0.6
          Low: <0.3
Key to Acronyms: ARV = antiretroviral; ETR= etravirine; PK = pharmacokinetic

 

Download Guidelines

Related Content

Email News letter Updates